Clinical trials: Neoplasms, Hematologic
Hematologic Malignancies
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
The purpose of this study is to see if a condensed version of the chemotherapy regimen busulfan, melphalan, fludarabine (bu/mel/flu) and the drug antithymocyte globulin (ATG-also referred to as rATG or thymoglobulin) can have the…
- Trial name
- NCT04098393
- Testing
- Busulfan 3.2 mg/kg/day, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer
This trial studies the effect of exercise and nicotinamide riboside on muscle health and insulin resistance in adult survivors of childhood cancer with prediabetes (elevated blood sugar level that is not high enough to be…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Prediabetes
- Trial name
- NCT05023993
- Testing
- Exercise Intervention, Nicotinamide Riboside
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Malignancy, Hematologic, Neoplasms, Hematologic
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes.
- Conditions
- Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer
- Trial name
- NCT06904066
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancies, Solid Tumors
Follow-Up for Study Participants Treated With an Allogeneic CAR T Cell Product
An observational, long-term follow up (LTFU) study of participants who received an allogeneic CAR T product in a prior clinical study.
- Trial name
- NCT06925685
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Allogene Therapeutics
Core Binding Factor Alpha Subunits, Hematologic Neoplasms
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
Background: Some blood cancers can be caused by germline variants (changes) in a person s RUNX1 gene. Germline variants are genetic inherited changes a person is born with.
- Conditions
- Core Binding Factor Alpha Subunits, Hematologic Neoplasms, Leukemia, Lymphoma
- Trial name
- NCT07524530
- Testing
- Cyclophosphamide, Busulfan, Fludarabine
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression
Why Patients Decline or Are Being Deemed Ineligible to Receive Home-based Treatment: a Mixed Methods Study
Treatment for blood cancers has improved significantly, and more patients are now living longer. However, these treatments are often intensive and long-lasting, and many patients experience serious side effects and symptoms.
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Multiple Myeloma Progression, Multiple Myeloma Refractory
- Trial name
- NCT07634263
- Where
- 3 sites in Denmark
- Volunteers
- 50 people
- Sponsor
- Odense University Hospital
Chimeric Antigen Receptor T-cell Therapy, Hematologic Malignancy
Symptom Monitoring and Management Intervention After CAR-T
The goal of this study is to refine and test a digital intervention named WAYPOINT to help patients monitor and manage symptoms after CAR-T therapy.
- Trial name
- APPROACH (NCT07886190)
- Testing
- WAYPOINT
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Massachusetts General Hospital
Polycythemia Vera (SNOMED CT: 109992005)
Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera
This is a Phase 2 trial to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of oral epetraborole tablets for the treatment of adults with phlebotomy-dependent polycythemia vera (PV).
- Trial name
- NCT07891533
- Testing
- Epetraborole
- Where
- Australia
- Volunteers
- 75 people
- Sponsor
- AN2 Therapeutics, Inc
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01199562
- Testing
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- City of Hope Medical Center
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Lyphoma, B-Cell, Leukemia, B-cell
Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Background: Gene therapy is a way to treat or prevent disease using genes. It is monitored very closely by regulators because there can be long-term, unexpected side effects.
- Conditions
- Lyphoma, B-Cell, Leukemia, B-cell, Multiple Myeloma, Hematologic Malignancies
- Trial name
- NCT02473757
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
This is a phase II multi-center, open label, single arm study to evaluate the safety and efficacy of Isatuximab administered intravenously in combination with CyBorD induction treatment and Lenalidomide maintenance treatment in a…
- Trial name
- NCT04786028
- Testing
- Isatuximab
- Where
- 7 sites in Canada
- Volunteers
- 72 people
- Sponsor
- Canadian Myeloma Research Group
Acute Lymphoid Leukemia, Acute Myeloid Leukemia
Prophylactic DLI-X for Leukemia Relapse After HCT
The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo)…
- Conditions
- Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL), Myelodysplastic Syndrome
- Trial name
- NCT07254793
- Testing
- Exercise Mobilized Prophylactic DLI, Standard Prophylactic DLI
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Arizona
Thrombocytopenia, Platelet Transfusion
Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia
The goal of this single-center, non-controlled, non-randomized exploratory clinical trial is To develop and validate a clinical-biological score (VISCOTHEM score) incorporating viscoelastometric tests parameters; based on an…
- Conditions
- Thrombocytopenia, Platelet Transfusion, Haemorrhage, Hematologic Malignancies
- Trial name
- VISCOTHEM-2 (NCT07653672)
- Testing
- Additional blood sample
- Where
- France
- Volunteers
- 410 people
- Sponsor
- Centre Hospitalier Annecy Genevois
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases
This phase I trial studies the side effects and best dose of ropidoxuridine when given together with whole brain radiation therapy in treating patients with cancer that has spread to the brain (brain metastases).
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
- Trial name
- NCT02993146
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment
- Where
- 14 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Wide Spectrum of Diseases, Hematologic Diseases
Data Collection of Standard Care and Evaluation of NHLBI Patients and Donors
Background: Researchers seek ways to study people s medical problems in order to teach and further general knowledge. The ability to assess and treat people with a wide range of diseases is critical to training people to be good…
- Trial name
- NCT04450927
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Myelofibrosis
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
- Trial name
- TREG108 (NCT05423691)
- Testing
- CK0804
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cellenkos, Inc.
Myeloid Malignancy
Therapeutic RSK1 Targeting in Myeloid Malignancies
This study hypothesizes that PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), is safe and well tolerated in participants with myelofibrosis (MF) and myelodysplastic syndromes/myeloproliferative neoplasms…
- Trial name
- NCT07379125
- Testing
- PMD-026
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT02862275
- Testing
- Atezolizumab, Biopsy Procedure, Biospecimen Collection
- Where
- 9 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated…
- Conditions
- Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis, Systemic Mastocytosis With an Associated Hematologic Neoplasm, Mast Cell Leukemia
- Trial name
- NCT03580655
- Testing
- Avapritinib
- Where
- 32 sites in United States, Austria and 10 more
- Volunteers
- 107 people
- Sponsor
- Blueprint Medicines Corporation